Annual report pursuant to Section 13 and 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.19.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Aug. 20, 2018
Jul. 28, 2016
Jan. 26, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Intellectual property fees     $ 55,648      
Description for right to purchase perpetual rights     North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.      
Amortization expenses       $ 1,963 $ 27,767  
Impairment loss       250,000    
Carrying value       0    
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]            
Aggregate purchase price, value $ 236,000          
Aggregate purchase price, Shares 10,000          
Naltrexone Implant Formulation [Member] | New Zealand from Trinity Compound Solutions [Member]            
Aggregate purchase price, value $ 236,000          
Aggregate purchase price, Shares 20,000          
Therakine, Ltd. [Member]            
License cost   $ 2,750,000        
Aggregate purchase price, value   $ 250,000   $ 250,000   $ 250,000
Escrow deposit         $ 75,000  
Therakine, Ltd. [Member] | Minimum [Member]            
Milestone payments and royalties   5.00%        
Therakine, Ltd. [Member] | Maximum [Member]            
Milestone payments and royalties   12.00%